Obseva Logo highresolution.jpg
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
10 déc. 2021 01h00 HE | ObsEva SA
  -Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3...
Obseva Logo4 (00000002).jpg
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
04 mai 2021 01h00 HE | ObsEva SA
  - EDELWEISS 3 trial of Yselty® expected to report topline data as planned in Q4:21-   GENEVA, Switzerland and BOSTON, MA – May 4, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a...
logo_new.jpg
ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
22 avr. 2020 16h30 HE | ObsEva SA
   Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolixSmall, expected, non-clinically relevant increases in serum lipids...
logo_new.jpg
ObsEva Provides Update Related to COVID-19 Pandemic
23 mars 2020 02h00 HE | ObsEva SA
  Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20, as planned PROLONG trial results expected to be announced in 2H:20, as...
logo_new.jpg
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
11 oct. 2019 01h00 HE | ObsEva SA
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while...
logo_new.jpg
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
09 mai 2019 01h00 HE | ObsEva SA
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
03 mai 2019 01h00 HE | ObsEva SA
                     Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and...
logo_new.jpg
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain
28 sept. 2018 01h00 HE | ObsEva SA
Linzagolix overall efficacy and safety maintained or improved at week 24 Linzagolix 75mg once daily showed no clinically significant impact on Bone Mineral Density (BMD), supporting further...